Merck makes a big bet in autoimmunity:

"Aqilion has persuaded Merck its preclinical project can overcome the barriers. The biotech has created selective TAK1 inhibitors with applications in autoimmune and inflammatory diseases."

https://www.fiercebiotech.com/biotech/merck-kgaa-spying-major-market-pays-aqilion-eu10m-tackle-tough-autoimmune-target